Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.2%

7 terminated out of 53 trials

Success Rate

76.7%

-9.9% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

30%

7 of 23 completed with results

Key Signals

7 with results77% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (12)
P 1 (8)
P 2 (18)
P 3 (3)

Trial Status

Completed23
Recruiting8
Unknown7
Terminated7
Active Not Recruiting4
Withdrawn2

Trial Success Rate

76.7%

Benchmark: 86.6%

Based on 23 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT05899361Not ApplicableCompleted

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

NCT07827612Phase 2Not Yet Recruiting

A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

NCT04579380Phase 2Active Not Recruiting

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT07741617Phase 2Not Yet RecruitingPrimary

A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

NCT07741435Recruiting

Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia

NCT07739121Recruiting

Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations

NCT06237920Phase 2Active Not RecruitingPrimary

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT03091192Phase 3Active Not Recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT07643415Not ApplicableRecruitingPrimary

Spinal Versus General Anesthesia in Open Simple Prostatectomy

NCT03595813Not ApplicableCompleted

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

NCT07481851Recruiting

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients

NCT03288545Phase 1Terminated

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT06680089Phase 2RecruitingPrimary

CD70-targeted immunoPET Imaging of Kidney Cancer

NCT06353906Phase 2RecruitingPrimary

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

NCT06676527Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT05935748Phase 2Terminated

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NCT04442724Not ApplicableRecruiting

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT05887245Active Not Recruiting

Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy

NCT03081858Phase 1Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT03219333Phase 2Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Scroll to load more

Research Network

Activity Timeline